A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

After decades of fits and starts, scientists finally got the world’s first vaccines against respiratory syncytial virus ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides effective protection against respiratory syncytial virus-related lower respiratory ...

The Danish nationwide cohort study analysed data from 5,289 adults (≥18 years) diagnosed with RSV-ARI between 2011 and 2022, comparing them to 15,867 matched controls from the general population.

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

GSK plc has announced that the Advisory Committee on Immunization Practices (ACIP) voted in favour of recommending the use of ...

A single dose of the RSVPreF3 OA vaccine offers strong protection against RSV-related lower respiratory tract disease in ...